Press Releases Lumosa Therapeutics Co., Ltd.

Equities

6535

TW0006535008

End-of-day quote Taipei Exchange Other stock markets 03:30:00 16/05/2024 am IST			5-day change	1st Jan Change
183.5 ^TWD	0.00%		-2.65%	+168.67%

14/05	Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson	CI
14/05	Lumosa Therapeutics Co., Ltd. Announces the Change in Juristic-Person Director Representative	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lumosa Therapeutics : Board Approved the Revised Exclusive Licensing Agreement for the Veterinary Analgesic	09/22/09	PU
Lumosa Therapeutics : Board Approved the Binding Term Sheet for LT1001, a Long-acting Analgesic Injection, with a Pakistani Pharmaceutical Company	09/22/09	PU
Lumosa Therapeutics : Board of Directors approved the Cancellation of Restricted Shares to Employees Stock Awards	09/22/09	PU
Lumosa Therapeutics : Board of Directors approved the consolidated financial report for the second quarter of 2022	09/22/09	PU
Lumosa Therapeutics : Partner, AMed Co., Informed the Receipt of Market Authorization from Malaysia NPRA for Naldebain, an Extended-Release Analgesic Injection	05/22/05	PU
Lumosa Therapeutics : Board Approved the Amendments for the Exclusive Licensing Agreement for the Veterinary Analgesic	31/22/31	PU
Lumosa Therapeutics : Shareholders' Meeting approved to release the company's directors from non-competition restrictions	24/22/24	PU
Lumosa Therapeutics : Important resolutions of LUMOSA's 2022 Annual Shareholders' Meeting	24/22/24	PU
Lumosa Therapeutics : Announcement of cancellation of part of new restricted employee shares by relevant authority	20/22/20	PU
Lumosa Therapeutics : Board of Directors not to proceed with the private placement of ordinary shares approved by the 2021 annual general meeting of shareholders	22/22/22	PU
Lumosa Therapeutics : Board of Directors approved the Cancellation of Restricted Shares to Employees Stock Awards	22/22/22	PU
LUMOSA Therapeutics : announces TFDA’s clearance of Phase 2 IND application for multiple-dose of LT3001 in patients with acute ischemic stroke.	24/22/24	PU
Lumosa Therapeutics : Board of Directors approved the convening of the 2022 Annual shareholders' Meeting	04/22/04	PU
Lumosa Therapeutics : Board of Directors approved to issue common shares via private placement.	04/22/04	PU
Lumosa Therapeutics : Board of Directors approved the 2021 consolidated financial report	04/22/04	PU
Lumosa Therapeutics : Receives the Results of LT1001 Phase 3 Trial Conducted by Chinese Partner, Jemincare	25/22/25	PU
Lumosa Therapeutics : Announcement of cancellation of part of new restricted employee shares by relevant authority	23/22/23	PU
Lumosa Therapeutics : Announces US FDA Clearance of IND Application for a Phase 2 Multi-Dose Study of LT3001 in Patients with Acute Ischemic Stroke.	09/22/09	PU
Lumosa Therapeutics : Announces the Termination of “Comparative BA Study” for Naldebain, a New Long-Acting Analgesic Injection, in the US Due to Additional USFDA Requirements	26/22/26	PU
Lumosa Therapeutics : Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke	03/21/03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lumosa Therapeutics Co., Ltd.

Equities

6535

TW0006535008

Press Releases

Filters